|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics. CA Cancer J Clin. 62:10–29. 2012.
|
|
2
|
Ajani JA, Fodor MB, Tjulandin SA, et al:
Phase II multi-institutional randomized trial of docetaxel plus
cisplatin with or without fluorouracil in patients with untreated,
advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol.
23:5660–5667. 2005. View Article : Google Scholar
|
|
3
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
et al: Phase III study of docetaxel and cisplatin plus fluorouracil
compared with cisplatin and fluorouracil as first-line therapy for
advanced gastric cancer: a report of the V325 Study Group. J Clin
Oncol. 24:4991–4997. 2006.PubMed/NCBI
|
|
4
|
Díaz-Rubio E, Gómez-España A, Massutí B,
et al: First-line XELOX plus bevacizumab followed by XELOX plus
bevacizumab or single-agent bevacizumab as maintenance therapy in
patients with metastatic colorectal cancer: the phase III MACRO TTD
study. Oncologist. 17:15–25. 2012.PubMed/NCBI
|
|
5
|
Perren TJ, Swart AM, Pfisterer J, et al: A
phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med.
365:2484–2496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ohtsu A, Shah MA, Van Cutsem E, et al:
Bevacizumab in combination with chemotherapy as first-line therapy
in advanced gastric cancer: a randomized, double-blind,
placebo-controlled phase III study. J Clin Oncol. 29:3968–3676.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Koizumi W, Narahara H, Hara T, et al: S-1
plus cisplatin versus S-1 alone for first-line treatment of
advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet
Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koizumi W, Akiya T, Sato A, et al: Phase
II study of S-1 as first-line treatment for elderly patients over
75 years of age with advanced gastric cancer: the Tokyo Cooperative
Oncology Group study. Cancer Chemother Pharmacol. 65:1093–1099.
2010.PubMed/NCBI
|
|
9
|
Shah MA, Jhawer M, Ilson DH, et al: Phase
II study of modified docetaxel, cisplatin, and fluorouracil with
bevacizumab in patients with metastatic gastroesophageal
adenocarcinoma. J Clin Oncol. 29:868–874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
El-Rayes BF, Zalupski M, Bekai-Saab T, et
al: A phase II study of bevacizumab, oxaliplatin, and docetaxel in
locally advanced and metastatic gastric and gastroesophageal
junction cancers. Ann Oncol. 21:1999–2004. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sibille A, Wauters I and Vansteenkiste J:
Maintenance therapy for advanced non-small-cell lung cancer: ready
for clinical practice? Expert Rev Anticancer Ther. 12:529–539.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ahn MJ, Sun JM, Ahn JS and Park K: The
effectiveness of maintenance pharmacotherapies for non-small cell
lung cancer. Clin Med Insights Oncol. 6:253–262. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Grossi F: Management of non-small cell
lung in cancer patients with stable disease. Drugs. 72:20–27. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zuniga RM, Torcuator R, Jain R, et al:
Rebound tumour progression after the cessation of bevacizumab
therapy in patients with recurrent high-grade glioma. J Neurooncol.
99:237–242. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ajani JA, Rodriguez W, Bodoky G, et al:
Multicenter phase III comparison of cisplatin/S-1 with
cisplatin/infusional fluorouracil in advanced gastric or
gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin
Oncol. 28:1547–1553. 2010. View Article : Google Scholar
|
|
16
|
Seol YM, Song MK, Choi YJ, et al: Oral
fluoropyrimidines (capecitabine or S-1) and cisplatin as first line
treatment in elderly patients with advanced gastric cancer: a
retrospective study. Jpn J Clin Oncol. 39:43–48. 2009. View Article : Google Scholar : PubMed/NCBI
|
